Related Experiment Videos
Amputation and dexniguldipine as treatment for canine appendicular osteosarcoma
K A Hahn1, A M Legendre, H M Schuller
1Carcinogenesis and Developmental Therapeutics Program, College of Veterinary Medicine, University of Tennessee, Knoxville 37901-1071, USA.
Journal of Cancer Research and Clinical Oncology
|January 1, 1997
Summary
Dexniguldipine shows promise in treating canine osteosarcoma by inhibiting cancer cell growth. While effective, it resulted in shorter survival times compared to cisplatin in this dog cancer study.
Area of Science:
- Veterinary Oncology
- Pharmacology
- Cancer Biology
Background:
- Canine osteosarcoma mirrors human disease, making dogs a valuable model.
- Metastatic disease is common at diagnosis, necessitating systemic therapy.
- Protein-kinase-C (PKC) inhibitors, like dexniguldipine, show anti-cancer potential.
Purpose of the Study:
- To evaluate the therapeutic efficacy of dexniguldipine in dogs with naturally occurring osteosarcoma.
- To compare dexniguldipine treatment with standard therapy (cisplatin) and no treatment.
Main Methods:
- Prospective, randomized clinical trial involving dogs with appendicular osteosarcoma.
- Three groups: no drug treatment (control), cisplatin treatment, and dexniguldipine treatment.
- All dogs underwent amputation prior to drug administration.
Main Results:
- Both dexniguldipine and cisplatin treatments significantly improved remission duration and survival compared to controls.
- Dexniguldipine treatment led to a shorter survival time than cisplatin treatment.
- Dexniguldipine demonstrated significant activity in inhibiting canine osteosarcoma micrometastases.
Conclusions:
- Dexniguldipine exhibits significant activity against canine osteosarcoma micrometastases.
- Further clinical investigation is warranted to optimize dexniguldipine dosage and its role in osteosarcoma treatment.
- The canine osteosarcoma model is responsive to antiproliferative agents like dexniguldipine.